Could a new Antibody-Lowering drug ease autoimmune brain inflammation?

NCT ID NCT07583641

Not yet recruiting Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This Phase 2 trial tests efgartigimod PH20 SC, a drug that lowers harmful antibodies, in 170 adults and teens with autoimmune encephalitis (AIE). Participants receive either the drug or a placebo, and researchers measure changes in disability and symptoms over up to 3 years. The goal is to see if the drug can safely improve outcomes for people with this rare brain condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: efgartigimod PH20 SC (a drug that lowers harmful antibodies)
What this could lead to: If it works, this could point toward a new treatment option for autoimmune encephalitis, potentially reducing disability and improving daily function.
What could go wrong: This is an early Phase 2 trial with only 170 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AUTOIMMUNE ENCEPHALITIS (AE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune disorder of the nervous system autoimmune encephalitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AUTOIMMUNE ENCEPHALITIS (AE)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.